SSY GROUP (02005) has obtained the drug production registration approval from the National Medical Products Administration for fumaric acid foscarnet tablets (20mg and 10mg).
Shi Si Pharmaceutical Group (02005) announced that the group has obtained approval from the China National Medical Products Administration (National Medical Products Administration)...
SSY GROUP (02005) announced that the Group has obtained the drug production registration approval from the China National Medical Products Administration (NMPA) for fumarate vonoprazan tablets (20mg and 10mg), which belong to Class 4 of chemical drugs and are considered to have passed consistency evaluation. Fumarate vonoprazan tablets are mainly used to treat reflux esophagitis.
The Group's fumarate vonoprazan active pharmaceutical ingredients have already been approved and registered by the NMPA for use in market preparations.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
